Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-177 vipivotide tetraxetan vs observation in PSMA-positive oligometastatic prostate cancer
2022-502956-29-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Nov 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing Lu-177 vipivotide tetraxetan arm with Observation arm (2 arms). Primary endpoint: Metastasis-free survival (MFS) by BIRC. Planned start Nov 2023; status: authorised.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-502956-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502956-29-00.